11/13
08:00 am
evax
Evaxion receives and appeals delisting determination from Nasdaq, remains committed to Nasdaq listing
High
Report
Evaxion receives and appeals delisting determination from Nasdaq, remains committed to Nasdaq listing
11/12
08:00 am
evax
Evaxion announces positive preclinical data for cytomegalovirus (CMV) vaccine program EVX-V1
High
Report
Evaxion announces positive preclinical data for cytomegalovirus (CMV) vaccine program EVX-V1
11/1
08:15 am
evax
Evaxion Biotech A/S (NASDAQ: EVAX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $14.00 price target on the stock.
Medium
Report
Evaxion Biotech A/S (NASDAQ: EVAX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $14.00 price target on the stock.
10/31
08:00 am
evax
Evaxion announces business update and third quarter 2024 financial results
Medium
Report
Evaxion announces business update and third quarter 2024 financial results
10/28
08:00 am
evax
Evaxion to announce business update and third quarter 2024 financial results on October 31
Low
Report
Evaxion to announce business update and third quarter 2024 financial results on October 31
10/11
02:09 pm
evax
OTC Markets Hosts Virtual Investor Presentation with Christian Kanstrup, CEO of Evaxion Biotech, and Brad Sorensen, Senior Analyst at Zacks SCR [Yahoo! Finance]
Medium
Report
OTC Markets Hosts Virtual Investor Presentation with Christian Kanstrup, CEO of Evaxion Biotech, and Brad Sorensen, Senior Analyst at Zacks SCR [Yahoo! Finance]
10/9
08:00 am
evax
Strong validation of Evaxion’s AI-Immunology™ platform in multiple clinical trials
Medium
Report
Strong validation of Evaxion’s AI-Immunology™ platform in multiple clinical trials
10/3
08:00 am
evax
Recent clinical data confirms significantly improved predictive power of Evaxion's AI-Immunology™ platform
Low
Report
Recent clinical data confirms significantly improved predictive power of Evaxion's AI-Immunology™ platform
9/26
12:16 pm
evax
Evaxion Biotech A/S (NASDAQ: EVAX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $14.00 price target on the stock.
Low
Report
Evaxion Biotech A/S (NASDAQ: EVAX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $14.00 price target on the stock.
9/26
07:30 am
evax
Evaxion significantly expands vaccine development collaboration with MSD
Low
Report
Evaxion significantly expands vaccine development collaboration with MSD
9/20
08:12 am
evax
Evaxion Biotech A/S (NASDAQ: EVAX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $14.00 price target on the stock.
Low
Report
Evaxion Biotech A/S (NASDAQ: EVAX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $14.00 price target on the stock.
9/19
08:00 am
evax
Evaxion launches improved AI-Immunology™ platform for vaccine antigen prediction
Medium
Report
Evaxion launches improved AI-Immunology™ platform for vaccine antigen prediction
9/16
07:00 am
evax
Evaxion reports convincing one-year data from phase 2 trial on AI-designed personalized cancer vaccine EVX-01
Medium
Report
Evaxion reports convincing one-year data from phase 2 trial on AI-designed personalized cancer vaccine EVX-01
9/9
08:00 am
evax
Evaxion reports 69% Overall Response Rate in its phase 2 trial on lead cancer vaccine candidate EVX-01
Medium
Report
Evaxion reports 69% Overall Response Rate in its phase 2 trial on lead cancer vaccine candidate EVX-01
9/9
07:00 am
evax
Evaxion obtains pre-clinical Proof-of-Concept for mRNA Gonorrhea vaccine candidate EVX-B2
Medium
Report
Evaxion obtains pre-clinical Proof-of-Concept for mRNA Gonorrhea vaccine candidate EVX-B2
8/29
09:07 am
evax
Evaxion Biotech A/S (NASDAQ:EVAX): Is Breakeven Near? [Yahoo! Finance]
High
Report
Evaxion Biotech A/S (NASDAQ:EVAX): Is Breakeven Near? [Yahoo! Finance]